Rhythm Pharmaceuticals, Inc.
(NASDAQ : RYTM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.82%179.480.0%$1747.94m
NVAXNovavax, Inc. -0.78%97.6778.2%$695.65m
AMGNAmgen, Inc. -0.54%232.581.4%$533.10m
BIIBBiogen, Inc. -0.42%232.831.8%$502.06m
GILDGilead Sciences, Inc. -0.87%69.821.0%$467.59m
BNTXBioNTech SE -0.91%167.690.0%$447.55m
REGNRegeneron Pharmaceuticals, Inc. 2.33%625.482.7%$405.42m
ILMNIllumina, Inc. 2.56%392.953.3%$395.51m
VRTXVertex Pharmaceuticals, Inc. 0.25%231.651.9%$335.05m
SNSSSunesis Pharmaceuticals, Inc. 0.33%3.010.7%$210.41m
EXASEXACT Sciences Corp. 0.97%78.1717.9%$155.65m
ARNAArena Pharmaceuticals, Inc. -0.21%91.7913.7%$145.12m
ALNYAlnylam Pharmaceuticals, Inc. 0.73%140.208.2%$140.13m
INCYIncyte Corp. 0.69%75.532.4%$133.83m
BMRNBioMarin Pharmaceutical, Inc. 1.07%87.644.2%$107.34m

Company Profile

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.